Intellia Therapeutics (NTLA) EBITDA (2015 - 2026)
Intellia Therapeutics (NTLA) reported EBITDA of -$97.5 million for Q1 2026, up 14.38% year-over-year from -$85.2 million in Q1 2025, and down 1.84% on a QoQ basis from -$95.7 million in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of EBITDA data on file, last reported at -$97.5 million in Q1 2026.
- Quarterly EBITDA rose 14.38% year-over-year to -$97.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$395.9 million (up 24.43% YoY) and the FY2025 annual result came in at -$412.3 million, up 20.46% from the prior year.
- EBITDA slipped to -$97.5 million in Q1 2026 per NTLA's latest filing, from -$95.7 million in the prior quarter.
- Across five years, EBITDA topped out at -$95.7 million in Q4 2025 and bottomed at -$152.3 million in Q1 2022.
- The 5-year median for EBITDA is -$113.0 million (2022), against an average of -$116.7 million.
- The widest annual swing landed in 2022, when EBITDA tumbled 229.53%; it then surged 35.43% in 2023.
- Tracing NTLA's EBITDA over 5 years: stood at -$111.5 million in 2022, then decreased by 17.35% to -$130.8 million in 2023, then retreated by 0.57% to -$131.6 million in 2024, then grew by 27.24% to -$95.7 million in 2025, then declined by 1.84% to -$97.5 million in 2026.
- Per Business Quant, the three latest NTLA EBITDA figures stand at -$97.5 million (Q1 2026), -$95.7 million (Q4 2025), and -$101.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -97.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.50 Mn |
| Dec 31, 2025 | -95.74 Mn |
| Sep 30, 2025 | -100.99 Mn |
| Jun 30, 2025 | -101.66 Mn |
| Mar 31, 2025 | -113.88 Mn |
| Dec 31, 2024 | -131.59 Mn |
| Sep 30, 2024 | -131.26 Mn |
| Jun 30, 2024 | -147.18 Mn |
| Mar 31, 2024 | -108.26 Mn |
| Dec 31, 2023 | -130.85 Mn |
| Sep 30, 2023 | -121.93 Mn |
| Jun 30, 2023 | -124.87 Mn |
| Mar 31, 2023 | -98.34 Mn |
| Dec 31, 2022 | -111.50 Mn |
| Sep 30, 2022 | -113.04 Mn |
| Jun 30, 2022 | -102.17 Mn |
| Mar 31, 2022 | -152.30 Mn |
| Dec 31, 2021 | -83.70 Mn |
| Sep 30, 2021 | -71.81 Mn |
| Jun 30, 2021 | -68.81 Mn |
| Mar 31, 2021 | -46.22 Mn |
| Dec 31, 2020 | -42.22 Mn |
| Sep 30, 2020 | -27.96 Mn |
| Jun 30, 2020 | -32.61 Mn |
| Mar 31, 2020 | -31.69 Mn |
| Dec 31, 2019 | -28.35 Mn |
| Sep 30, 2019 | -23.55 Mn |
| Jun 30, 2019 | -25.49 Mn |
| Mar 31, 2019 | -21.85 Mn |
| Dec 31, 2018 | -19.09 Mn |
| Sep 30, 2018 | -22.70 Mn |
| Jun 30, 2018 | -22.22 Mn |
| Mar 31, 2018 | -21.36 Mn |
| Dec 31, 2017 | -24.72 Mn |
| Sep 30, 2017 | -15.88 Mn |
| Jun 30, 2017 | -16.02 Mn |
| Mar 31, 2017 | -12.95 Mn |
| Dec 31, 2016 | -10.82 Mn |
| Sep 30, 2016 | -7.70 Mn |
| Jun 30, 2016 | -6.95 Mn |
| Mar 31, 2016 | -6.69 Mn |
| Dec 31, 2015 | -5.49 Mn |
| Sep 30, 2015 | -3.30 Mn |
| Jun 30, 2015 | -3.42 Mn |
| Mar 31, 2015 | -1.20 Mn |